Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.
Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
JCI Insight. 2018 Jul 12;3(13):95319. doi: 10.1172/jci.insight.95319.
The maintenance of effective immunity over time is dependent on the capacity of hematopoietic stem cells (HSCs) to sustain the pool of immunocompetent mature cells. Decline of immune competence with old age may stem from HSC defects, including reduced self-renewal potential and impaired lymphopoiesis, as suggested in murine models. To obtain further insights into aging-related alteration of hematopoiesis, we performed a comprehensive study of blood hematopoietic progenitor cells (HPCs) from older humans. In the elderly, HPCs present active oxidative phosphorylation and are pressed to enter cell cycling. However, p53-p21 and p15 cell senescence pathways, associated with telomerase activity deficiency, strong telomere attrition, and oxidative stress, are engaged, thus limiting cell cycling. Moreover, survival of old HPCs is impacted by pyroptosis, an inflammatory form of programmed cell death. Lastly, telomerase activity deficiency and telomere length attrition of old HPCs may be passed on to progeny cells such as naive T lymphocytes, further highlighting the poor hematopoietic potential of the elderly. This pre-senescent profile is characteristic of the multiple intrinsic and extrinsic factors affecting HPCs in elderly individuals and represents a major obstacle in terms of immune reconstitution and efficacy with advanced age.
随着时间的推移,有效免疫的维持依赖于造血干细胞(HSCs)维持免疫活性成熟细胞库的能力。衰老导致免疫能力下降可能源于 HSC 缺陷,包括自我更新潜力降低和淋巴生成受损,正如在鼠模型中所表明的那样。为了进一步了解与衰老相关的造血变化,我们对老年人的血液造血祖细胞(HPC)进行了全面研究。在老年人中,HPC 存在活跃的氧化磷酸化,并被推向细胞周期。然而,与端粒酶活性缺乏、强烈的端粒磨损和氧化应激相关的 p53-p21 和 p15 细胞衰老途径被激活,从而限制了细胞周期。此外,衰老 HPC 的存活受到细胞焦亡的影响,这是一种程序性细胞死亡的炎症形式。最后,衰老 HPC 中端粒酶活性的缺乏和端粒长度的磨损可能会传递给幼稚 T 淋巴细胞等祖细胞,这进一步突出了老年人造血潜力差的问题。这种衰老前的特征是影响老年人 HPC 的多种内在和外在因素的特征,这是随着年龄增长进行免疫重建和治疗效果的主要障碍。